The emerging role of photodynamic therapy in the treatment of cutaneous infections.

Publication date: Nov 29, 2024

Cutaneous infections pose ongoing challenges to standard treatments due to resistance and limited efficacy. Photodynamic therapy (PDT) emerges as a promising supplement or an alternative to address complicated cases. In this review, we comprehensively review PDT’s safety and efficacy in treating cutaneous infections. A PubMed systematic review with search terms for PDT treatment, hair, skin, and nail infections. There were a total of 43 studies on the use of PDT in cutaneous infections which discussed the treatment of viral (N. =20), bacterial (N. =11), fungal (N. =9), and protozoal (N. =3) infections. There is evidence for using PDT, mostly 5-aminolevulinic acid (5-ALA) and methyl aminolevulinate (MAL), in the treatment of cutaneous infections. Most evidence for viral infections involved treatment with 5-ALA PDT in condyloma acuminatum (CoAc), verruca vulgaris, and molluscum contagiosum. In bacterial infections, 5-ALA and MB PDT have been used to achieve complete remission in refractory Pseudomonas and atypical mycobacteria infections without recurrence. In onychomycosis, MAL PDT achieved a 40. 9% cure rate and MB PDT showed a 77. 8-100% cure rate with no reports of recurrence. Parasitic infections, such as leishmaniasis have also been successfully treated with both 5-ALA and MAL PDT. PDT is a promising treatment option for cutaneous infections, with growing evidence for its utility in treating cutaneous bacterial, viral, fungal, and parasitic infections, particularly those that fail standard treatments. Side effects were mostly limited to localized pain with good outcomes and low recurrence rates.

Concepts Keywords
Mycobacteria Ala
Photodynamic Bacterial
Promising Cutaneous
Therapy Efficacy
Viral Evidence
Infections
Limited
Pdt
Photodynamic
Recurrence
Standard
Therapy
Treatment
Treatments
Viral

Semantics

Type Source Name
disease IDO role
disease MESH infections
drug DRUGBANK Aminolevulinic acid
drug DRUGBANK Methyl aminolevulinate
disease MESH viral infections
disease MESH verruca
disease MESH molluscum contagiosum
disease MESH bacterial infections
disease MESH recurrence
disease MESH onychomycosis
disease MESH Parasitic infections
disease MESH leishmaniasis
pathway KEGG Leishmaniasis

Leave a Comment

Your email address will not be published. Required fields are marked *